The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease

Kidney and Blood Pressure Research

Volumn 33, Issue 2, 2010, Pages 129-138

  Becker, Jan Ulrich ^b,c   Opazo Saez, Anabelle ^a   Zerres, Klaus ^d   Witzke, Oliver ^a   Hoyer, Peter Friedrich ^a   Schmid, Kurt Werner ^b   Kribben, Andreas ^a   Bergmann, Carsten ^d,e   Nürnberger, Jens ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Institute of Pathology and Neuropathology   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e Bioscientia Center for Human Genetics   (Germany)

Author keywords

Autosomal recessive polycystic kidney disease; Cystic kidney disease; MTOR

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; TUBERIN; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BILE DUCT; CELLULAR DISTRIBUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CELL; KIDNEY DISTAL TUBULE; KIDNEY POLYCYSTIC DISEASE; LIVER; MALE; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; TISSUE DISTRIBUTION; ANIMAL; CHEMISTRY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METABOLISM; PATHOLOGY;

ADOLESCENT; ANIMALS; BILE DUCTS; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY TRANSPLANTATION; LIVER; LIVER TRANSPLANTATION; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; PROTEIN-SERINE-THREONINE KINASES; TOR SERINE-THREONINE KINASES;

EID: 77951967599     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314380     Document Type: Article

References (21)

1. Wilson PD: Polycystic kidney disease. N Engl J Med 2004; 350: 151-164.
2. Walz G: Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol Dial Transplant 2006; 21: 1752-1757.
3. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-MTOR pathway in human disease. Nat Genet 2005; 37: 19-24.
4. Wullschleger S, Loewith R, Hall MN: Tor signaling in growth and metabolism. Cell 2006; 124: 471-484.
5. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mtor pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
6. Harris TE, Lawrence JC Jr: Tor signaling. Sci STKE 2003; 2003:re15.
7. Wahl PR, Hir ML, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, Serra AL, Wuthrich RP: Mitotic activation of akt signaling pathway in han:Sprd rats with polycystic kidney disease. Nephrology (Carlton) 2007; 12: 357-363.
8. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51.
9. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wuthrich RP: Inhibition of mtor with sirolimus slows disease progression in han:Sprd rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604.
10. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259.
11. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz- Broeking E, Renken C, Nizze H, Querfeld U, Rudolph B, Mueller-Wiefel DE, Bergmann C, Haffner D: Activation of the AKT/MTOR pathway in autosomal recessive polycystic kidney disease (AR PKD). Nephrol Dial Transplant 2009; 24: 1819- 1827.
12. Edelstein CL: Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1219-1226.
13. Nurnberger J, Kavapurackal R, Zhang SJ, Opazo Saez A, Heusch G, Philipp T, Pietruck F, Kribben A: Differential tissue distribution of the invs gene product inversin. Cell Tissue Res 2006; 323: 147-155
14. Bergmann C, Senderek J, Schneider F, Dornia C, Kupper F, Eggermann T, Rudnik- Schoneborn S, Kirfel J, Moser M, Buttner R, Zerres K: Pkhd1 mutations in families requesting prenatal diagnosis for autosomal recessive polycystic kidney disease (AR PKD). Human mutation 2004; 23: 487-495. (Pubitemid 38569222)
15. Avruch J, Belham C, Weng Q, Hara K, Yonezawa K: The p70 s6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol 2001; 26: 115-154.
16. Kenerson HL, Aicher LD, True LD, Yeung RS: Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002; 62: 5645-5650.
17. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE: The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001; 59: 126-136.
18. Phillips CL, Miller KJ, Filson AJ, Nurnberger J, Clendenon JL, Cook GW, Dunn KW, Overbeek PA, Gattone VH 2nd, Bacallao RL: Renal cysts of inv/inv mice resemble early infantile nephronophthisis. J Am Soc Nephrol 2004; 15: 1744-1755.
19. Woollard JR, Punyashtiti R, Richardson S, Masyuk TV, Whelan S, Huang BQ, Lager DJ, Van Deursen J, Torres VE, Gattone VH, LaRusso NF, Harris PC, Ward CJ: A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int 2007; 72: 328-336.
20. Rossetti S, Harris PC: Genotype-phenotype correlations in autosomal dominant and autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2007; 18: 1374-1380. (Pubitemid 46717503)
21. Holz MK, Ballif BA, Gygi SP, Blenis J: Mtor and s6k1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005; 123: 569-580.